Seagen, a wholly owned subsidiary of Pfizer

How to interpret these research links

Connected source records

The exact organization name Seagen, a wholly owned subsidiary of Pfizer appears in 18 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials18

Recruiting shown3

Roles1

SourceClinicalTrials.gov

Clinical trials

18 shown

A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsNCT06131840 · lead sponsor · 2023-11-20

RECRUITING

A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762 · lead sponsor · 2022-10-25

RECRUITING

A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632 · lead sponsor · 2020-06-08

RECRUITING

A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsNCT06549816 · lead sponsor · 2024-08-21

COMPLETED

A Study of SGN-MesoC2 in Advanced Solid TumorsNCT06466187 · lead sponsor · 2024-08-02

TERMINATED

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892 · lead sponsor · 2024-05-20

ACTIVE_NOT_RECRUITING

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerNCT06012435 · lead sponsor · 2024-02-21

ACTIVE_NOT_RECRUITING

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2NCT06003231 · lead sponsor · 2023-11-14

ACTIVE_NOT_RECRUITING

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsNCT05983133 · lead sponsor · 2023-11-14

TERMINATED

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsNCT05571839 · lead sponsor · 2023-01-03

TERMINATED

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · lead sponsor · 2022-03-07

ACTIVE_NOT_RECRUITING

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsNCT05194072 · lead sponsor · 2022-01-12

TERMINATED

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsNCT04609566 · lead sponsor · 2021-01-26

COMPLETED

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsNCT04579380 · lead sponsor · 2021-01-11

ACTIVE_NOT_RECRUITING

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerNCT04539938 · lead sponsor · 2020-12-01

COMPLETED

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerNCT03975647 · lead sponsor · 2019-10-02

ACTIVE_NOT_RECRUITING

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsNCT03485209 · lead sponsor · 2018-06-25

ACTIVE_NOT_RECRUITING

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerNCT04220203 · lead sponsor

APPROVED_FOR_MARKETING

Drugs studied in this sponsor's trials

16 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Seagen, a wholly owned subsidiary of Pfizer as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

tucatinib6

pembrolizumab5

trastuzumab3

carboplatin2

cisplatin2

placebo2

ado-trastuzumab emtansine1

bevacizumab1

Sponsor roles

lead sponsor18

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.